Overview A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer Status: Not yet recruiting Trial end date: 2023-03-30 Target enrollment: Participant gender: Summary To evaluate the efficacy, safety and pharmacokinetic characteristics of HR070803 in the treatment of advanced esophageal cancer. Phase: Phase 2 Details Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.